Abstract

Doxorubicin causes cardiotoxicity and exercise intolerance. Pre-conditioning exercise training seems to prevent doxorubicin-induced cardiac damage. However, the effectiveness of the cardioprotective effects of exercise training concomitantly with doxorubicin treatment remains largely unknown. To determine whether low-to-moderate intensity aerobic exercise training during doxorubicin treatment would prevent cardiotoxicity and exercise intolerance, we performed exercise training concomitantly with chronic doxorubicin treatment in mice. Ventricular structure and function were accessed by echocardiography, exercise tolerance by maximal exercise test, and cardiac biology by histological and molecular techniques. Doxorubicin-induced cardiotoxicity, evidenced by impaired ventricular function, cardiac atrophy, and fibrosis. Exercise training did not preserve left ventricular ejection fraction or reduced fibrosis. However, exercise training preserved myocardial circumferential strain alleviated cardiac atrophy and restored cardiomyocyte cross-sectional area. On the other hand, exercise training exacerbated doxorubicin-induced body wasting without affecting survival. Finally, exercise training blunted doxorubicin-induced exercise intolerance. Exercise training performed during doxorubicin-based chemotherapy can be a valuable approach to attenuate cardiotoxicity.

Highlights

  • Doxorubicin (Doxo) is an antineoplastic agent widely used to treat various cancer types over the last decades

  • We considered as significant a P ≤ 0.05

  • Doxo-Induced LVEF Reduction Is Not Prevented by Exercise training (ExTr)

Read more

Summary

Introduction

Doxorubicin (Doxo) is an antineoplastic agent widely used to treat various cancer types over the last decades. Clinically overt cardiotoxicity occurs in ∼6% of cancer patients, at least one in seven patients will present subclinical cardiotoxicity, and 1 out of 10 will experience an adverse cardiovascular event [8]. This borderline impairment of ventricular function may not reach the minimum guideline-levels for starting a pharmacological intervention during cancer treatment, but it might account for the high incidence of cardiovascular morbidity and mortality observed in previously treated patients, even several years after defeating cancer [9, 10]. Finding strategies to prevent Doxo-related adverse effects are highly desirable

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call